ReviewClinical therapeutics2017
Drugs and Medical Devices: Adverse Events and the Impact on Women's Health.
Review in Clinical therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Female participation in randomized controlled trials of motor rehabilitation after spinal cord injury: a systematic review.Spinal cord · 2026Pooled it
- A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Aging of Nonhuman Primate Eyes Is Sexually Dimorphic.Investigative ophthalmology & visual science · 2026Article
- Article
- How Does Biological Sex Impact Mucosal Bacterial Infection? Mucosal Defenses and Bacterial Detection.Immunological reviews · 2026Review
- Evaluating sex as a biological variable in in vitro blood-brain barrier models: insights from primary mouse brain endothelial cells.Fluids and barriers of the CNS · 2026Article
- Sex as a biological variable and pre-specified sub-subgroup analyses: what would Sir James Black and Sir Richard Peto say?European heart journal · 2026Article
- Early control or gradual relief? Gender-specific real-world insights into omalizumab response in chronic spontaneous urticaria patients.The World Allergy Organization journal · 2026Article
- Aligning femtech innovation With equity: a strategic framework for real world impact.Frontiers in global women's health · 2026Article
- Inclusion and reporting by age, sex, and ethnicity in clinical studies of high-risk medical devices approved in the European Union.European heart journal. Quality of care & clinical outcomes · 2025Article
- Global perspectives to enhance strategies for advancing women in healthcare and STEMM leadership.Immunology and cell biology · 2025Review
- Recommendations for a Better Understanding of Sex and Gender in the Neuroscience of Mental Health.Biological psychiatry global open science · 2024Review
- The Appropriateness of Medical Devices Is Strongly Influenced by Sex and Gender.Life (Basel, Switzerland) · 2024Review
- Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.BMC pharmacology & toxicology · 2024Article
- Integrating sex and gender into biomedical research requires policy and culture change.npj women's health · 2024Article
- Sex differences in patterns of white matter neuroplasticity after balance training in young adults.Frontiers in human neuroscience · 2024Article
- Best practices for recruitment in veterinary clinical trials.Frontiers in veterinary science · 2024Review
- The relationship between gender and pharmacology.Current research in pharmacology and drug discovery · 2024Article
- Retinal morphology across the menstrual cycle: insights from the UK Biobank.npj women's health · 2024Article
- Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A large number of medications and medical devices removed from the market by the US Food and Drug Administration over the past 4 decades specifically posed greater health risks to women. This article reviews the historical background of sex and gender in clinical research policy and describes several approved drugs and devices targeted for use in women that have caused major morbidity and mortality. The intended population for the medications and devices, population affected, approval process, and the basic and legal actions taken against the medication/drug company are also discussed. It is recognized that women are still at risk for harm from unsafe medications and devices, and continued improvements in legislation that promotes inclusion of sex and gender into the design and analysis of research will improve safety for both men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.